Publication | Open Access
Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer Immunotherapy (Adv. Mater. 22/2023)
81
Citations
0
References
2023
Year
NanoparticlesNanotherapeuticsImmunologyImmunotherapeuticsBiomedical EngineeringImmunotherapyReactive Oxygen SpeciesNanomedicineTumor ImmunologyTherapeutic NanomaterialsTumor ImmunityChemodynamic TherapyCopper CombinedRadiation OncologyHealth SciencesRos Responsive NanoparticlesTumor TargetingEnhanced Cancer ImmunotherapyNovel Therapeutic StrategyTumor MicroenvironmentSynergistic Cancer ImmunotherapyImmune Checkpoint InhibitorNano-drug DeliveryMedicineCancer Therapeutics
Immunotherapy In article 2212267, Haihua Xiao, Nianzeng Xing, and co-workers present a novel therapeutic strategy to achieve synergistic cancer immunotherapy via cuproptosis induced by reactive oxygen species (ROS)-responsive nanomedicine loaded with elesclomol and copper ([email protected]). With this approach, the tumor microenvironment is reprogrammed, and the expression of PD-L1 is increased, which consequently improves responsiveness of immunotherapy.